AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

被引:434
|
作者
Gavine, Paul R. [1 ]
Mooney, Lorraine [1 ]
Kilgour, Elaine [1 ]
Thomas, Andrew P. [1 ]
Al-Kadhimi, Katherine [1 ]
Beck, Sarah [1 ]
Rooney, Claire [1 ]
Coleman, Tanya [1 ]
Baker, Dawn [1 ]
Mellor, Martine J. [1 ]
Brooks, A. Nigel [1 ]
Klinowska, Teresa [1 ]
机构
[1] AstraZeneca R&D, Shanghai, Peoples R China
关键词
CANCER CELL-LINES; MULTIPLE-MYELOMA; IN-VIVO; MUTATIONS; APOPTOSIS; EXPRESSION; RESISTANCE; CARCINOMA; AZD2171; TRANSLOCATION;
D O I
10.1158/0008-5472.CAN-11-3034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are currently in clinical development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity. Here, we report the pharmacologic profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression. In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR. Importantly, at efficacious doses, no evidence of anti-KDR-related effects were observed, confirming the in vivo FGFR selectivity of AZD4547. Taken together, our findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models. AZD4547 is under clinical investigation for the treatment of FGFR-dependent tumors. Cancer Res; 72(8); 2045-56. (C) 2012 AACR.
引用
收藏
页码:2045 / 2056
页数:12
相关论文
共 50 条
  • [31] Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase
    Bin Yang, E
    Wei, L
    Zhang, K
    Chen, YZ
    Chen, WN
    JOURNAL OF BIOCHEMISTRY, 2006, 139 (03): : 495 - 502
  • [32] A potent inhibitor of platelet-derived growth factor receptor tyrosine kinase
    Min, DS
    Lee, YH
    Kang, LW
    Byoun, CH
    Chang, JS
    Ryn, SH
    Suh, PG
    MOLECULES AND CELLS, 1996, 6 (04) : 463 - 468
  • [33] Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase Inhibitor
    Cee, Victor J.
    Schenkel, Laurie B.
    Hodous, Brian L.
    Deak, Holly L.
    Nguyen, Hanh N.
    Olivieri, Philip R.
    Romero, Karina
    Bak, Annette
    Be, Xuhai
    Bellon, Steve
    Bush, Tammy L.
    Cheng, Alan C.
    Chung, Grace
    Coats, Steve
    Eden, Patrick M.
    Hanestad, Kelly
    Gallant, Paul L.
    Gu, Yan
    Huang, Xin
    Kendall, Richard L.
    Lin, Min-Hwa Jasmine
    Morrison, Michael J.
    Patel, Vinod F.
    Radinsky, Robert
    Rose, Paul E.
    Ross, Sandra
    Sun, Ji-Rong
    Tang, Jin
    Zhao, Huilin
    Payton, Marc
    Geuns-Meyer, Stephanie D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) : 6368 - 6377
  • [34] AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
    Yao, Ting-Jing
    Zhu, Jin-Hai
    Peng, De-Feng
    Cui, Zhen
    Zhang, Chao
    Lu, Pei-hua
    TUMOR BIOLOGY, 2015, 36 (07) : 5641 - 5648
  • [35] Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist
    De Savi, Chris
    Bradbury, Robert H.
    Rabow, Alfred A.
    Norman, Richard A.
    Buttar, David
    Currie, Gordon S.
    Weir, Hazel
    Donald, Craig
    Andrews, David
    MacFaul, Phil
    Ballard, Peter
    Curwen, Jon
    Wilson, Zena
    Richmond, Graham
    D'Cruz, Celina
    Powell, Steve
    Walker, Graeme
    Hulse, Michael
    Tonge, Michael
    CANCER RESEARCH, 2015, 75
  • [36] YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors
    Amino, N
    Ideyama, Y
    Yamano, M
    Kuromitsu, S
    Tajinda, K
    Samizu, K
    Hisamichi, H
    Matsuhisa, A
    Shirasuna, K
    Kudoh, M
    Shibasaki, M
    CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1630 - 1638
  • [37] AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
    Chresta, Christine M.
    Davies, Barry R.
    Hickson, Ian
    Harding, Tom
    Cosulich, Sabina
    Critchlow, Susan E.
    Vincent, John P.
    Ellston, Rebecca
    Jones, Darren
    Sini, Patrizia
    James, Dominic
    Howard, Zoe
    Dudley, Phillippa
    Hughes, Gareth
    Smith, Lisa
    Maguire, Sharon
    Hummersone, Marc
    Malagu, Karine
    Menear, Keith
    Jenkins, Richard
    Jacobsen, Matt
    Smith, Graeme C. M.
    Guichard, Sylvie
    Pass, Martin
    CANCER RESEARCH, 2010, 70 (01) : 288 - 298
  • [38] The discovery of YM-60828: A potent, selective and orally-bioavailable Factor Xa inhibitor
    Hirayama, F
    Koshio, H
    Katayama, N
    Kurihara, H
    Taniuchi, Y
    Sato, K
    Hisamichi, N
    Sakai-Moritani, Y
    Kawasaki, T
    Matsumoto, Y
    Yanagisawa, I
    BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (05) : 1509 - 1523
  • [39] In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor.
    Luettgen, Joseph M.
    Bozarth, Tracy A.
    Bozarth, Jeffrey M.
    Barbera, Frank A.
    Lam, Patrick Y.
    Quan, Mimi L.
    Pinto, Donald J.
    Wexler, Ruth R.
    Rendina, Alan R.
    Knabb, Robert M.
    BLOOD, 2006, 108 (11) : 112B - 112B
  • [40] Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor
    Magone, M. Teresa
    Hartle, Iris R.
    Fitzgibbon, Edmond
    Bishop, Rachel
    Arango, Mike
    Moran, Susan
    Vold, Roo
    del Rivero, Jaydira
    Pozo, Karen
    Streit, Jamie
    Roszko, Kelly L.
    Collins, Michael T.
    Gafni, Rachel I.
    OPHTHALMOLOGY, 2021, 128 (04) : 624 - 626